Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age, \>18 years, AND~* Capable of understanding the purpose and risks of the study and have provided a signed and dated written IC, AND~* Prior to the study baseline, been treated with oral steroid medication, of which \> 2 weeks on oral prednisone equivalent of at least 40mg/day, and still have:~  * active ulcerative colon disease documented by a MAYO score of 6-11, and~ * active ulcerative colon disease documented by a MTWSI score of 7-15~OR~* Prior to the study baseline, documented clinical inability to decrease or stop the course of oral steroid medication. Subjects have been treated for a minimum of 12 weeks, and still have:~  * chronic active ulcerative colon disease documented by a MAYO score of 6-11, and~ * chronic active ulcerative colon disease documented by a MTWSI score of 7-15~OR~* Prior to the study baseline, been treated with a stable dosage of azathioprine for a minimum of 12 weeks, and have a moderate to severe relapse defined as:~  * chronic active ulcerative colon disease documented by a MAYO score of 6-11, and~ * chronic active ulcerative colon disease documented by a MTWSI score of 7-15.~Exclusion Criteria:~* UC, requiring immediate surgical, endoscopic, or radiological intervention; including massive haemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or peri-anal abscesses) or toxic colon,~* history of large bowel surgery,~* history of serious infections,~* positive stool cultures, including Clostridium difficile,~* significant organ dysfunction,~* pregnancy, nursing mothers, or women of childbearing potential without appropriate use of contraceptives,~* treatment with:~  1. an altered dose of any 5-ASA preparation within 4 weeks of screening,~ 2. an altered dose of azathioprine or mercaptopurine within 4 weeks of screening (stable dosage of immunosuppressives is allowed), or start of azathioprine in the last 3 months prior to baseline,~ 3. probiotics, antibiotics within 1 month, methotrexate or cyclosporine within 2 months prior to screening,~ 4. any experimental treatment for this population e.g. infliximab, tacrolimus, FK506 or other anti TNFα therapy) within 2 months of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BIAP

Based on this trial design, predict the completion outcome and termination type (if applicable).